Gilead Sciences Inc. won approval from the US FDA on Nov. 10 for its second generation hepatitis B drug Vemlidy; the compound will be priced in line with its predecessor drug, Gilead's own Viread, at $997.77 per month on the US market.
Unusually, Vemlidy also gained a positive recommendation from the European Medicines Agency's scientific committee, the CHMP, for use in hepatitis...






